Argentina’s latest cannabis law established new regulations for its cannabis industry framework.
Argentina, which legalized medical cannabis and hemp in 2022, created the Regulatory Agency for the Hemp and Medicinal Cannabis Industry (ARICCAME) in January of this year to promote and administer the country’s cannabis industry, and on August 4th the agency released a decree outlining several new regulations that will be enacted (1,2).
“The publication of this decree marks the dawn of a new age in Latin America when it comes to industrial hemp and cannabis,” said Lorenzo da Silva, President of the Latin American Industrial Hemp Association (LAIHA) (1). “Argentina, due to its geographical positioning and land availability, long history in agriculture and a commodity-centered economy, is the most suitable country in all of Latin America to develop a sturdy and sustainable hemp industry.”
The decree itself echoed the promotion of the various advantageous positions of Argentina to produce cannabis and hemp (1). The government has stated that it aims to use cannabis production to improve regional economies, enhance its exports, and improve product development and research (1).
As newly mandated, the tetrahydrocannabinol (THC) limit for hemp is set at 1% (1). Cannabidiol (CBD) products remain legal only as imports for patients (1). Cannabis will be permitted for medical purposes, veterinary use, nutritional and cosmetic uses, plus research (3).
The ARRICAME is intended to unify the administrative process of the industry and will oversee consumer safety, promote scientific research, and work with institutions of higher learning and state agencies (1). A new 20-person advisory board for the ARRICAME must include representatives from various relevant organizations and half of the members must be either women or transgender (1).
"There is no possibility of industry development without a federal perspective of support for regional economies with added value,” explained Gabriel Giménez, a board member of ARICCAME (2). “We have the opportunity to create quality employment, impact on the domestic market, and, above all, decent wages. That is already a concrete possibility. We have the responsibility to bring industrial hemp to small and medium-sized producers."
References
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.